Laverock Therapeutics Expands Seed Funding to Over £20m with Mercia Ventures' Support

Laverock Therapeutics, a gene silencing company, has extended its seed funding round to exceed £20 million. The company, specializing in advanced gene therapies, is supported by Mercia Ventures and other investors such as Calculus Capital, Eli Lilly and Company, Eos Advisory, Maven Capital Partners, and newcomer Norcliffe Capital. Gene silencing, which leverages the body's own mechanisms to modify gene expression, is seen as a promising field in medicine for treating various conditions, including cancer and genetic diseases. Laverock's platform uses microRNAs to regulate gene expression, showing enhanced results in targeting solid tumors. Founded by biotech entrepreneur David Venables in 2021, the company aims to use the new funds to advance in vivo studies and establish partnerships for integrating their technologies into broader therapeutic applications.